| [1] |
Reyes VE，Al-Saleem T，Robu VG，et al.Extra nodal NK/TCell lymphoma nasal type：efficacy of pegaspargase report of two patients from the united sates and review of literature[J].Leuk Res，2010，34（1）：50-52.
|
| [2] |
Zhou Z，Li Z，Sun Z，et al.S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine[J].Sci Rep，2016，6（29）：23-25.
|
| [3] |
Tse E，Kwong YL.The diagnosis and management of NK/T-cell lymphomas[J].J Hematol Oncol，2017，4（14）：85-88.
|
| [4] |
Wang J，Wang L，Liu C，et al.Efficacy of combined gemcitabine，oxaliplatin and pegaspargase （P-gemox regimen） in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma[J].Oncotarget，2016，7（20）：29 092-29 101.
|
| [5] |
Wang J，Wang H，Wang Y，et al.Analysis of the efficacy and safety of a combined gemcitabine，oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma[J].Oncotarget，2016，7（23）：35 412-35 422.
|
| [6] |
Lahoud OB.High-dose chemotherapy and autologous stem cell transplant in older patients with lymphoma[J].Am J Hematol，2018，6（1）：40-46.
|
| [14] |
Kallberg E，Vogl T，Liberg D，et al.S100A9 interaction with TLR4 promotes tumor growth[J].PLoS One，2012，7（3）：34 207-34 208.
|
| [7] |
Sun Y，Narayan VA，Wittenberg GM.Side effect profile similarities shared between antidepressants and immune-modulators reveal potential novel targets for treating major depressive disorders[J].BMC Pharmacol Toxicol，2016，10（21）：47-49.
|
| [8] |
Zhang L，Jia S，Ma Y，et al.Efficacy and safety of cisplatin，dexamethasone，gemcitabine and pegaspargase （DDGP） regimen in newly diagnosed，advanced-stage extranodal natural killer/T-cell lymphoma：interim analysis of a phase 4 study NCT01501149[J].Oncotarget，2016，7（34）：55 721-55 731.
|
| [9] |
Zhang L，Li S，Jia S，et al.The DDGP （cisplatin，dexamethasone，gemcitabine，and pegaspargase） regimen for treatment of extranodal natural killer （NK）/T-cell lymphoma，nasal type[J].Oncotarget，2016，7（36）：58 396-58 404.
|
| [10] |
Xu PP，Xiong J，Cheng S，et al.A phase Ⅱ study of Methotrexate，Etoposide，Dexamethasone and Pegaspargase sandwiched with radiotherapy in the treatment of newly diagnosed，stageⅠE toⅡE extranodal natural-killer/T-cell lymphoma，nasal-type[J].EBioMedicine，2017，25（1）：41-49.
|
| [11] |
Chang Y，Fu X，Sun Z，et al.Utility of baseline，interim and end-of-treatment（18）F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase[J].Sci Rep，2017，7（24）：41 057-41 059.
|
| [12] |
Liang J，Wang L，Peter Gale R，et al.Efficacy of pegaspargase，etoposide，methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA[J].Blood Cancer J，2017，7（9）：60-63.
|
| [13] |
Bu S，Yuan F，Wei X，et al.L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma[J].Exp Ther Med，2016，11（6）：2437-2445.
|
| [15] |
Gery S，Gombart AF，Yi WS，et al.Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia[J].Blood，2005，106（8）：2827-2836.
|
